Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;132(2):86-93.
doi: 10.1016/j.ymgme.2020.10.006. Epub 2020 Oct 14.

Proteomics for the study of new biomarkers in Fabry disease: State of the art

Affiliations
Review

Proteomics for the study of new biomarkers in Fabry disease: State of the art

Federica Rossi et al. Mol Genet Metab. 2021 Feb.

Abstract

Nephropathy represents a major complication of Fabry Disease and its accurate characterization is of paramount importance in predicting the disease progression and assessing the therapeutic responses. The diagnostic process still relies on performing renal biopsy, nevertheless many efforts have been made to discover early reliable biomarkers allowing us to avoid invasive procedures. In this field, proteomics offers a sensitive and fast method leading to an accurate detection of specific pathological proteins and the discovery of diagnostic and prognostic biomarkers that reflect disease progression and facilitate the evaluation of therapeutic responses. Here, we report a review of selected literature focusing on the investigation of several proteomic techniques highlighting their advantages, limitations and future perspectives in their application in the routine study of Fabry Nephropathy.

Keywords: Anderson-Fabry disease; Biomarkers; Clinical proteomics; Fabry nephropathy; Mass spectrometry; Matrix-assisted laser desorption/ionization.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest H.P.M. reports receiving grants from Alexion, Amicus, Sanofi Genzyme, and Shire. E.S. reports receiving grants from Sanofi Genzyme; positions on the advisory boards of Amicus and Sanofi Genzyme; speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.Pi. reports participation at advisory boards, speaker fees and travel support from Amicus, Sanofi Genzyme, and Shire-Takeda. F.R., V.L., A.S., M.M.B., F.M. and F.Pa. declare no conflict of interest.

LinkOut - more resources